116 terminated. 116 Phase 2, 35 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 116 | Terminated 116 |
| Phase 1 | 35 | Terminated 35 |
| Phase 3 | 6 | Terminated 6 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-03 |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer Fluorouracil, Leucovorin, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | Baylor College of Medicine | 3 | 2024-03-06 | 2026-04-09 |
| Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma Infigratinib - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | LianBio LLC | 6 | 2023-10-19 | 2024-08-14 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. Indocyanine green - Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Terminated | Laval University | 11 | 2022-12-15 | 2024-04-02 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors NC410, pembrolizumab - Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 97 | 2022-10-06 | 2026-08-13 |
| A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) IMU-131, Ramucirumab plus Paclitaxel, Pembrolizumab - Gastric Cancer, Cancer of Stomach | Phase 2 | Terminated | Imugene Limited | 7 | 2022-08-17 | 2025-05-11 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Bemarituzumab, CAPOX, SOX - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Amgen | 72 | 2022-05-17 | 2026-07-29 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab - Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Fusion Pharmaceuticals Inc. | 6 | 2022-04-20 | 2023-12-19 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma CYNK-101, Pembrolizumab, Trastuzumab - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 1 | 2022-04-14 | 2024-12-12 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers SBT6050, trastuzumab deruxtecan, tucatinib - HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 / Phase 2 | Terminated | Silverback Therapeutics | 2 | 2022-02-08 | 2022-08-18 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors BNT141, Nab-paclitaxel, Gemcitabine - Solid Tumor, Gastric Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 13 | 2022-01-18 | 2024-10-02 |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. MRG003 - Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma | Phase 2 | Terminated | Lepu Biopharma Co., Ltd. | 6 | 2021-12-31 | 2026-09-09 |
| Milademetan in Advanced/Metastatic Solid Tumors RAIN-32 - Solid Tumors, Head and Neck Carcinoma | Phase 2 | Terminated | Rain Oncology Inc | 40 | 2021-11-01 | 2024-10-17 |
| Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab - Stomach Neoplasms, Esophagogastric Junction Disorder | Phase 2 | Terminated | Fudan University | 6 | 2021-09-28 | 2025-06-18 |
| A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer Amivantamab - Stomach Neoplasms, Esophageal Neoplasms | Phase 2 | Terminated | Janssen Pharmaceutical K.K. | 62 | 2021-08-30 | 2024-09-19 |
Showing 20 of 116. Sign in to see all of them.
Stomach Neoplasms (100) · Esophageal Neoplasms (27) · Colorectal Neoplasms (15) · Neoplasm Metastasis (14) · Breast Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (12) · Neoplasms (11) · Pancreatic Neoplasms (11) · Colonic Neoplasms (10) · Ovarian Neoplasms (10) · Gastroparesis (8) · Squamous Cell Carcinoma of Head and Neck (8) · Uterine Cervical Neoplasms (8) · Adenocarcinoma Of Esophagus (7) · Carcinoma, Hepatocellular (7)
Digestive System Diseases (115) · Gastrointestinal Diseases (115) · Digestive System Neoplasms (101) · Neoplasms by Site (100) · Gastrointestinal Neoplasms (96) · Neoplasms (92) · Esophageal Diseases (30) · Head and Neck Neoplasms (28) · Neoplasms by Histologic Type (27) · Pathological Conditions, Signs and Symptoms (25) · Neoplasms, Glandular and Epithelial (24) · Intestinal Diseases (23) · Carcinoma (22) · Endocrine System Diseases (22)
Capecitabine (18) · Oxaliplatin (13) · pembrolizumab (11) · Docetaxel (10) · Fluorouracil (10) · Trastuzumab (10) · Cisplatin (9) · Leucovorin (7) · Paclitaxel (6) · S 1 (combination) (5) · Ado-Trastuzumab Emtansine (3) · Epirubicin (3) · Irinotecan (3) · Nivolumab (3) · tegafur-gimeracil-oteracil (3)
Hoffmann-La Roche (4) · National Cancer Institute (NCI) (4) · Fudan University (3) · Alliance for Clinical Trials in Oncology (2) · Amgen (2) · Bristol-Myers Squibb (2) · Johns Hopkins University (2) · Memorial Sloan Kettering Cancer Center (2) · NextCure, Inc. (2) · Samsung Medical Center (2) · Trio Medicines Ltd. (2) · AC Camargo Cancer Center (1) · AHS Cancer Control Alberta (1) · Aduro Biotech, Inc. (1) · Aminex Therapeutics, Inc. (1)
United States (65) · South Korea (18) · Germany (15) · China (14) · Canada (13) · France (13) · Spain (13) · Italy (12) · United Kingdom (12) · Taiwan (10) · Australia (9) · Belgium (9) · Japan (9) · Poland (6) · Brazil (5)
Mouen Khashab, MD (2) · Adrian Kilcoyne, MD (1) · Aiping Zhou, Doctor (1) · Akos Czibere, MD, PhD (1) · Alan Tan, MD (1) · Alexandre Brind'Amour, MD (1) · Andreas Kaubisch (1) · Andrew Blakely, M.D. (1) · Anish A Sheth, MD (1) · Ann-Lii Cheng (1) · Anna Dorothea Wagner, MD (1)
PMID 19738454, PMID 23622977, PMID 23848826, PMID 24824852, PMID 27342748, PMID 28343975, PMID 28576557, PMID 30706247, PMID 32584367, PMID 34398557, PMID 34951522, PMID 35176457, PMID 35623069, PMID 35764956, PMID 37530631, PMID 37678921, PMID 37860278, PMID 39432867, PMID 40341124, PMID 40554667, PMID 40632975, PMID 40672074, PMID 40762544, PMID 42259602, PMID 42371751
2019 (2), 2009 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), N01CM62204 (1), U01CA099118 (1), U10CA032102 (1), U10CA180821 (1)